Novartis Investor Relations Novartis ESMO Call Investor Presentation October 24, 2023 'IS | Reimagining Medicine Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "potential," "will," "planned," "pipeline," "outlook," or similar expressions, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvi ...